Based on the product's classification, Ломилан (loratadine) is a type of medicine generally used for managing symptoms associated with various allergic conditions. The therapeutic role is centered on managing conditions presenting with systemic or localized discomfort, including those linked to allergic rhinitis and chronic idiopathic urticaria.

Seasonal Allergy Relief: Pollen, Grass, and More

This category of use is relevant in contexts marked by increased discomfort or tension, addressing symptoms that become more disruptive during flare-ups caused by outdoor seasonal triggers. It helps address symptom clusters that may appear suddenly during phases when symptoms become more noticeable, often used when short-term symptomatic assistance is needed.

Year-Round Symptom Control: Indoor Allergens

This domain is applied across areas where additional symptomatic support is needed for conditions involving episodic or fluctuating manifestations caused by perennial allergens like dust or dander. It provides supportive relief when symptoms interfere with routine activities, supporting general well-being during symptomatic phases.

Managing Skin Discomfort: Hives and Itching

Ломилан is commonly used for managing conditions presenting with systemic or localized discomfort, such as hives. It helps manage symptoms that create noticeable physiological strain, supports patients during episodes of heightened discomfort, and contributes to easing the overall symptom load.

---

Quick Fact

This medicine is applied in scenarios where additional management of symptoms related to physical discomfort, such as itchy eyes or sneezing, is required.

Who Can and Cannot Use Ломилан?

Eligibility for using Ломилан (Loratadine), a second-generation antihistamine, is defined by regulatory agencies based on age, specific health conditions, and physiological states. This section outlines the official criteria for use.

---

Contraindications and Age Limitations

Classification	Population/Condition	Restriction Status
Absolute Contraindication	Known Hypersensitivity to Loratadine or any excipients	MUST NOT USE
Pediatric Use	Children under 2 years of age	Not Recommended/Not Established
Approved Use	Adults, Adolescents, and Children ge 2 years (liquid) or ge 6 years (tablet)	Allowed

---

Conditions Requiring Special Consideration

Official labeling specifies conditional use for certain populations:

• Severe Hepatic Impairment: Patients with severe liver disease require special consideration, often involving a reduced or alternate-day dosing regimen. This represents a conditional restriction on standard use.

• Severe Renal Impairment: Caution is advised, and dose adjustment may be necessary for individuals with severe kidney function impairment.

• Pregnancy and Lactation: Use during pregnancy and breastfeeding is generally not recommended. This status is due to limited data on safety in human pregnancy and the excretion of Loratadine into breast milk, respectively.

Interactions with other medicines and products

This section outlines the clinically significant interactions documented in official government regulatory information for Ломилан (Diphenoxylate Hydrochloride and Atropine Sulfate).

---

Pharmacodynamic Interaction Categories

Regulatory documents identify interactions primarily stemming from additive effects on the central nervous system (CNS) and interactions with specific antidepressant medications.

Interacting Medicinal Product Categories:

• Central Nervous System (CNS) Depressants: Co-administration with medicines that slow brain activity may lead to enhanced effects. Categories include opioids, barbiturates, benzodiazepines, muscle relaxants, general anesthetics, tranquilizers, and certain antipsychotics.
• Monoamine Oxidase Inhibitors (MAOIs): Specific medicines used to treat depression or Parkinson's disease, such as tranylcypromine sulphate or phenelzine sulphate, are cited as potentially interacting.

Interaction-Related Restrictions and Constraints:

Official labeling requires patients to inform a healthcare professional about the concurrent use of any of the listed interacting substances, including medicinal products and alcohol, when taking Ломилан. This procedural requirement is in place to allow for necessary monitoring or adjustments to the treatment plan.

Product-Specific Interaction:

• Alcohol: Official regulatory information specifies that the concomitant use of alcohol may interact with the drug.

How Ломилан Works

Primary Action: Selective H1 Receptor Blockade

Ломилан acts primarily as a selective antagonist of peripheral H1 histamine receptors. By competitively binding to these receptors, the drug stabilizes them in an inactive conformation. This mechanism prevents histamine—a key mediator released by mast cells and basophils—from initiating its signaling cascade. This action limits the activation driven by excessive mediator concentrations, resulting in the inhibition of downstream signal transduction within the targeted inflammatory pathways.

---

Modulating Peripheral Signaling Dynamics

The drug's primary mechanistic domain is the modulation of peripheral pathways that mediate histamine-driven signaling. It suppresses the signaling sequences that mediate the H1-driven changes in microvasculature. This selective peripheral activity is determined by the drug's low lipid solubility and limited crossing of the blood-brain barrier, allowing for localized peripheral antagonism that defines the mechanistic outcome without significant central nervous system pathway interference.

Administration Instructions for Ломилан (Loratadine)

Ломилан (Loratadine) is an oral medication that is typically taken once daily (o.d.). It can be administered with or without food (independently of mealtime).

---

Dosing Schedule and Age-Specific Rules

Administration is based on the patient's age and weight:

Age Group	Body Weight Criterion	Recommended Daily Dose
Adults & Adolescents	12 years of age and over	10 mg once daily
Children	30 kg or less (ages 2–12)	5 mg once daily
Children	More than 30 kg (ages 2–12)	10 mg once daily

Use in children under 2 years of age is generally not recommended due to insufficient data on safety and efficacy in that population. For patients with kidney or liver impairment, the dosing interval may require adjustment by a healthcare professional.

---

Administration Procedure and Missed Doses

Tablets should be swallowed whole with a glass of water. If the medicine is in a liquid form, use the calibrated measuring device provided, rather than a household spoon, to ensure accuracy. If an oral disintegrating tablet is used, it should be placed on the tongue and allowed to dissolve without chewing, and may be swallowed with or without water.

If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Do not take a double dose to compensate for a forgotten one.

Recent Clinical Evidence Overview

Research examining the study of Loratadine (Ломилан) was applied in studies examining patient-reported experiences related to allergic conditions, utilizing Randomized Controlled Trials (RCTs) and Systematic Reviews.

Evidence for Seasonal and Perennial Allergies

For Seasonal Allergic Rhinitis, studies monitored patient-reported outcomes describing perceived discomfort. Researchers examined key metrics such as Total Symptom Scores, which combine measures of sneezing, itching, runny nose, and eye irritation. Studies reported measurements of symptom scores over short follow-up periods, typically four to six weeks. Research also explored the time interval where subjects first reported a change in their perceived symptom intensity.

Research examined populations with persistent or year-round symptoms (Perennial Rhinitis) associated with allergens like dust mites. These studies monitored chronic symptoms over intermediate periods, sometimes extending up to five months, and included assessments of Quality of Life.

Evidence for Chronic Hives (Urticaria)

Research examined outcomes related to localized discomfort, focusing on measures like the severity of pruritus (itching) and the size and number of wheals. Studies observed the physiological response following administration, including measurements of the histamine-induced skin wheal and flare response.

Evidence Gaps and Limitations

Research results apply primarily to the specific populations studied (adults, adolescents, and children in some groups). Data regarding long-term outcomes (one year or more) are not fully established across all conditions, as follow-up durations were limited in many core trials. Research largely focused on common administration amounts, and comparative evidence against the newest treatments is sometimes lacking or findings were mixed.

Key Studies & References

1. Loratadine (MedlinePlus Drug Information)

Common questions about Ломилан (FAQ)

Q: What is Ломилан?

A: Ломилан is the brand name for the drug loratadine, a medication that belongs to a class of drugs called non-sedating antihistamines. Antihistamines work by blocking the effects of histamine, a natural substance in the body that causes allergy symptoms like itching, sneezing, and runny nose. Loratadine is commonly used to relieve symptoms associated with seasonal allergies, such as hay fever.

Q: What is the main use of Ломилан?

A: The main use of Ломилан is to treat symptoms of allergic rhinitis (hay fever), which can be seasonal or year-round. These symptoms typically include:

• Sneezing
• Runny or stuffy nose
• Itchy, watery eyes
• Itching of the nose or throat

It is also sometimes used to relieve symptoms of chronic urticaria (hives), such as itching and rash.

Q: Is Ломилан safe for children?

A: Yes, in general, loratadine (the active ingredient in Ломилан) is considered safe for use in children, provided it is used according to the product's label or a healthcare provider's instructions. The appropriate dosage depends on the child's age and weight. Products containing loratadine often come in different forms, such as syrup or chewable tablets, which are suitable for children. Always consult a healthcare provider before giving any medication to a child.

Q: What is the difference between sedating and non-sedating antihistamines?

A: Antihistamines are often classified as either sedating (first-generation) or non-sedating (second-generation). Ломилан (loratadine) is a non-sedating antihistamine.

• Sedating Antihistamines (e.g., diphenhydramine) can easily cross the blood-brain barrier and cause effects in the central nervous system, leading to drowsiness and impaired coordination.
• Non-Sedating Antihistamines (e.g., loratadine, cetirizine, fexofenadine) are less likely to cross the blood-brain barrier, which means they are less likely to cause drowsiness and are generally preferred for daytime use.

How to Store and Dispose of Ломилан

Official labeling defines strict requirements for the storage and disposal of Ломилан (loratadine) to maintain stability and prevent environmental harm.

---

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, typically between 20 C and 25 C.
Protection	Protect from excess heat, light, and moisture. Do not freeze the medicine.
Packaging	Keep the product in the original container. Liquid forms must be kept tightly closed.
Safety	Store strictly out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Ломилан must not be disposed of in household waste or wastewater. Dispose of the product in a manner that complies with local regulations for pharmaceutical waste, often requiring return to a pharmacy or designated collection site. Do not use the medicine past the expiry date printed on the packaging.